Prognostic Evaluation of Interleukin 17A and Myeloid-Derived Suppressor Cells in Colorectal Cancer Patients

Main Article Content

Ibrahim A Altememi
Osamah Abd Ali Nassr

Abstract

The current study was focused on patients with Colorectal Cancer between the ages of 26–82years. The objective of this study to determine the interleukin (IL-17) level and CD33 expression status in patients with Colorectal Cancer. A total of 60 out of (40 patients and 20 control groups) were collected from gastroenterology and liver diseases teaching hospital from March 2018–May 2018, Iraq. The results show Median IL-17 was significantly higher in study group than in control group (plessthan 0.001), 12.13 (9.73) pg/ml versus 0.41 (0.67) pg/ml, and Median CD33 was significantly higher in study group than in control group (plessthan 0.001), 73.00 (5.0) % versus 4.50 (3.75) %.

Article Details

Section
Research Article